US FDA approves ozanimod for the treatment of adults with moderately to severely active ulcerative colitis

Approval of the oral sphingosine 1-phosphate receptor modulator was based on data from the True North Phase III study, in which it met its primary endpoint of clinical remission during both the induction (18% versus 6% placebo) and maintenance (60% v 41%) phases (both p<0.0001).

Source:

Biospace Inc.